Accepted for Publication: September 18, 2022.
Published Online: November 30, 2022. doi:10.1001/jamadermatol.2022.4867
Corresponding Author: Arash Mostaghimi, MD, MPA, MPH, Department of Dermatology, Brigham and Women’s Hospital, 221 Longwood Ave, Boston, MA 02115 (amostaghimi@bwh.harvard.edu).
Author Contributions: Ms Drake and Dr Mostaghimi had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Reyes-Hadsall, Heinrich, Huang, Mostaghimi.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: Drake, Reyes-Hadsall, Martinez, Heinrich, Mostaghimi.
Critical revision of the manuscript for important intellectual content: Drake, Reyes-Hadsall, Huang, Mostaghimi.
Statistical analysis: Drake, Martinez.
Administrative, technical, or material support: Drake, Reyes-Hadsall, Martinez, Heinrich, Mostaghimi.
Supervision: Huang, Mostaghimi.
Other: Martinez.
Conflict of Interest Disclosures: Dr Huang reported personal fees from Concert and Pfizer outside the submitted work; holding patents for ALTO, BETA, and BELA licensed; and participation in alopecia-related clinical trials by Incyte, Lilly, Concert, and Aclaris, all outside the submitted work. Dr Mostaghimi reported consulting fees from Pfizer, Concert, Lilly, Hims and Hers, Equillium, AbbVie, Digital Diagnostics, and Bioniz, and grants from Pfizer, all outside the submitted work. No other disclosures were reported.
Disclaimer: Dr Arash Mostaghimi is an Associate Editor of JAMA Dermatology but was not involved in any of the decisions regarding review of the manuscript or its acceptance.